Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002624055 | SCV003513550 | benign | not provided | 2022-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004070675 | SCV004067975 | uncertain significance | not specified | 2023-06-30 | criteria provided, single submitter | clinical testing | The c.1102G>A (p.E368K) alteration is located in exon 1 (coding exon 1) of the GPR101 gene. This alteration results from a G to A substitution at nucleotide position 1102, causing the glutamic acid (E) at amino acid position 368 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |